At jCyte, we are committed to developing an effective stem cell therapy for retinitis pigmentosa (RP) and bringing it quickly to patients. The need is great. There are no medical treatments for RP.
To change that, Drs. Henry Klassen and Jing Yang have spent decades in the lab, investigating the mechanisms that drive RP and other retinal diseases. Their work led them to retinal progenitor cells (RPCs), a type of stem cell that...
At jCyte, we are committed to developing an effective stem cell therapy for retinitis pigmentosa (RP) and bringing it quickly to patients. The need is great. There are no medical treatments for RP.
To change that, Drs. Henry Klassen and Jing Yang have spent decades in the lab, investigating the mechanisms that drive RP and other retinal diseases. Their work led them to retinal progenitor cells (RPCs), a type of stem cell that can only become retinal cells.
Over time, Drs. Klassen and Yang learned to produce quality RPCs in large batches. In pre-clinical studies, they showed these cells could rescue, and even replace diseased retinal cells.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.